Expands Presence and Service Offerings in Strategic Growth MarketSINGAPORE, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OMS Energy Technologies Inc. (“OMS” or the “Company”) (NASDAQ: OMSE), a growth-oriented manufacturer of surface wellhead systems (“SWS”) and oil country tubular goods (“OCTG”) for the oil and gas industry, and its wholly-owned subsidiary, OMS Oilfield Services (Thailand) Ltd. (“OMS Thailand”), today announced an expansion of the Company’s long-standing partnership with one of Thailand’s foremost oil ...

HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amplify Energy Corp. (NYSE: AMPY) (“Amplify,” the “Company,” “us,” or “our”) announced a series of transactions that will result in a complete exit from its interests in East Texas, for a total anticipated combined consideration of $127.5 million: Haynesville Monetization Transaction: Amplify has sold its remaining interest in certain units with rights in the Haynesville basin, located in Harrison County, Texas, generating net proceeds of $5.5 million. This transac ...

Southern Expansion Hole Hits 46 Metres Averaging 1.10% CuMONTREAL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the “Company" or "Osisko Metals") (TSX: OM; OTCQX: OMZNF; FRANKFURT: 0B51) is pleased to announce new drill results from the Gaspé Copper Project, located in the Gaspé Peninsula of Eastern Québec. Osisko Metals CEO Robert Wares commented: “These latest results continue to confirm and expand our resource model with several long continuous intersections of copper and molybdenum mine ...

1.53 g/t Au over 85.3 meters, including 5.19 g/t Au over 9.1 meters in LBP1171 1.17 g/t Au over 59.4 meters, including 3.44 g/t Au over 15.2 meters in LBP1155 VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Liberty Gold Corp. (TSX: LGD; OTCQX: LGDTF) (“Liberty Gold” or the “Company”) is pleased to announce strong oxide gold assays from nine infill drill holes in the Discovery Zone at its Black Pine Gold Project (“Black Pine”) in southeastern Idaho. These results are part of the ongoing ~40,00 ...

Third Quarter 2025 Financial Results and Highlights Revenue of $75.3 million, an increase of 8% year-over-yearCloud ARR of $89 million, accelerating to 24% year-over-yearNon-GAAP diluted EPS of $0.28 vs. $0.23 in Q3 2024; GAAP diluted EPS of $0.13 vs. $0.07 in Q3 2024 TEL AVIV, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- - Radware® (NASDAQ: RDWR), a global leader in application security and delivery solutions for multi-cloud environments, today announced its consolidated financial results for the third quarte ...

Core Insights - Fangzhou Inc. and Shanghai Fosun Pharmaceutical have signed a strategic collaboration agreement to enhance AI-driven chronic disease management, focusing initially on psoriasis and autoimmune conditions [1][2][5] Group 1: Strategic Collaboration - The partnership aims to develop flagship digital health initiatives that integrate AI-assisted patient education, academic research dissemination, digital marketing, and long-term disease management [2] - This collaboration supports the Healthy China 2030 initiative, emphasizing the importance of chronic disease management in public health [2] Group 2: Technology and Innovation - Fangzhou will leverage its proprietary "XingShi" Large Language Model and "AI+H2H" ecosystem alongside Fosun Pharma's Otezla® to create a comprehensive AI-powered psoriasis management system [3] - The system will enable precision assessment, personalized treatment, and ongoing care support for patients [3][4] Group 3: Market Impact and Future Plans - The partnership is expected to accelerate the digital transformation of pharmaceutical care, reshaping psoriasis management through AI-driven innovation [6] - Fangzhou plans to expand its "AI+" ecosystem beyond weight management to include psoriasis and other chronic diseases, contributing to a healthier China [7] Group 4: Company Background - Fangzhou Inc. serves 52.8 million registered users and 229,000 physicians, specializing in tailored medical care and AI-enabled precision medicine solutions [9] - Fosun Pharma, founded in 1994, is a leading global healthcare company involved in pharmaceuticals, medical devices, and healthcare services [8]

Core Viewpoint - Northern Horizon Capital AS has received approval from the Estonian Financial Supervision and Resolution Authority for the sale of its shares to private investors, indicating a significant change in ownership structure [1][2]. Group 1: Transaction Details - The sale involves all 12,500 shares of Northern Horizon Capital AS, previously held by Northern Horizon A/S, to Antanas Anskaitis, Antanas Danys, and Tomas Milašauskas [1]. - This transaction follows the signing of a share purchase agreement with the partners of Grinvest on 21 August 2025, and is expected to be completed within 10 days of the approval [2]. Group 2: Company Background - Northern Horizon Capital AS manages the Baltic Horizon Fund, which is a registered contractual public closed-end real estate fund [3]. - Grinvest, the private investment firm involved in the transaction, has interests in commercial property, transportation, and infrastructure [4].

Core Insights - SUTNTIB AB Tewox has published its factsheet detailing financial indicators and key events as of September 30, 2025 [1] Group 1: Key Events in Q3 2025 - Construction has commenced for three new grocery stores in Vilnius, Klaipėda, and Klaipėda district, with openings planned for 2026 [4] - The Vilnius store will have a Gross Leasable Area (GLA) of approximately 1,788 sqm, leased to the supermarket chain Iki, with a total investment of around 5 million EUR [4] - The Klaipėda store will feature a GLA of approximately 2,127 sqm, leased to Lidl, with a total investment projected at around 6 million EUR [4] - The grocery store in Klaipėda district will have a GLA of approximately 2,000 sqm, leased to Iki, with a total investment of around 5 million EUR [4] Group 2: Financial Performance - The company published its unaudited interim consolidated and separate financial statements for the first half of 2025 [4] - Consolidated operating income for the first half of 2025 reached 7 million EUR, while comprehensive income was 3.5 million EUR [4] - Total assets amounted to 179.6 million EUR as of the reporting period [4]

Core Insights - Royal Philips announced results from the iMODERN trial, which evaluated the safety and effectiveness of immediate versus delayed treatment of additional narrowed arteries in heart attack patients [1][3][5] - The study found no significant difference in major outcomes between immediate treatment during the first procedure and staged treatment, providing evidence for both approaches [3][5][13] Group 1: iMODERN Trial Findings - The iMODERN trial is the largest study to date testing instantaneous wave-free ratio (iFR) in acute heart attack settings, enrolling 1,146 patients across 41 hospitals in 14 countries [5][3] - The main endpoint of the study combined three outcomes: death, another heart attack, or hospitalization for heart failure over three years, with no significant differences found between the two treatment strategies [5][3] - The results confirm that both immediate and staged treatment strategies are backed by solid evidence, allowing for more personalized care for patients [5][6] Group 2: Clinical Implications - The findings support current international guideline recommendations for complete revascularization in STEMI patients, integrating physiological assessment into treatment decisions [6][5] - The study provides cardiologists with the confidence to offer a complete solution in one session when appropriate, addressing a long-standing question in interventional cardiology [5][6] - Flexibility in treatment approaches is emphasized, as some patients may benefit from immediate treatment while others may be better served by waiting for further evaluation [6][5] Group 3: Related Studies - The ILIAS ANOCA study presented at the same conference demonstrated the value of physiology-guided decision-making in patients with angina and no obstructive coronary arteries, showing significant improvements in patient-reported symptoms [7][8] - The ILIAS ANOCA study involved 153 patients and confirmed the benefits of tailored therapy guided by coronary function testing [8][7] Group 4: Technology Utilization - Philips' iFR technology and advanced cardiac MRI were utilized in the iMODERN trial to guide treatment decisions, supporting the generation of robust evidence for clinical practice [9][10] - The integration of these technologies allows for both invasive and non-invasive approaches in evaluating treatment strategies for heart attack patients [9][10]

Group 1 - Sampo Group will publish its Interim Statement for January–September 2025 on 5 November 2025 at approximately 8:30 am Finnish time [1] - The report will include an investor presentation and a video review featuring Group CEO Morten Thorsrud, available on the company's website [1] - A conference call for investors and analysts will take place on 5 November at 10:30 am Finnish time, with registration required for participation [2][3] Group 2 - Key executives including Group CEO Morten Thorsrud, Group CFO Knut Arne Alsaker, and Head of IR Sami Taipalus will attend the conference call [3] - The conference call will be accessible live on the company's website, with a recorded version available later [3] - For further inquiries, Antti Järvenpää, Investor Relations Specialist, can be contacted [3]